Amikacin injection 250 mg is used to treat a variety of serious bacterial infections [1]. It is an aminoglycoside antibiotic effective against many Gram-negative bacteria, as well as some Gram-positive bacteria [2].
What specific infections does amikacin treat?
Amikacin injection is often prescribed for infections that are resistant to other, less potent antibiotics [3]. This includes conditions such as complicated urinary tract infections, respiratory tract infections like pneumonia, intra-abdominal infections, skin and bone infections, and septicemia [2]. It can also be used in cases of endocarditis, particularly when caused by susceptible organisms [2].
How does amikacin work?
Amikacin functions by inhibiting bacterial protein synthesis [4]. It binds to the 30S ribosomal subunit of susceptible bacteria, interfering with the accurate reading of mRNA and leading to the production of non-functional proteins, ultimately causing bacterial cell death [4].
What are the potential side effects of amikacin?
Like other aminoglycosides, amikacin carries a risk of nephrotoxicity (kidney damage) and ototoxicity (damage to hearing and balance) [5]. These risks are dose-dependent and can be exacerbated by pre-existing kidney impairment or concurrent use of other nephrotoxic or ototoxic drugs [5]. Other potential side effects include neurotoxicity, rash, fever, and blood dyscrasias [2]. Regular monitoring of kidney function and hearing may be necessary during treatment [5].
What is the typical dosage and administration for amikacin injection?
Dosage for amikacin injection is typically based on patient weight and kidney function, administered either intramuscularly or intravenously [2]. The 250 mg strength is one available concentration, with others also existing to meet different dosage requirements [1].
When does amikacin patent protection expire?
Information regarding patent exclusivity for specific amikacin formulations and their associated patents can be tracked through resources like DrugPatentWatch.com, which provides data on drug patents and their expiration dates [6].